Physician profile
Prashant Soni
NPI 1003969056
$895.02
in general payments reported to CMS, 2019-2025
25 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $15.60 · 2021: $52.05 · 2022: $55.38 · 2023: $240 · 2024: $126 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $225.25 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Mentor Worldwide LLC | $86.34 | 2023-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Smith+Nephew, INC. | $53.12 | 2024-2025 | Stravix, Grafix |
| Alexion Pharmaceuticals, INC. | $44.55 | 2019 | |
| Leo Pharma INC. | $39.42 | 2023 | Adbry |
| Acelrx Pharmaceuticals, INC. | $36.86 | 2021 | |
| Allergan, INC. | $33.97 | 2021-2022 | |
| Janssen Biotech, INC. | $33.74 | 2019 | |
| Tela Bio, INC. | $33.33 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Glaxosmithkline, LLC. | $25.85 | 2025 | Nucala |
| Musculoskeletal Transplant Foundation INC. | $24.26 | 2024 | |
| Jazz Pharmaceuticals INC. | $23.51 | 2019 | |
| Eisai INC. | $22.73 | 2019 | |
| Arcutis Biotherapeutics, INC. | $21.16 | 2023 | |
| Lilly USA, LLC | $20.09 | 2024 | Taltz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $20.01 | 2022 | |
| Kerecis Limited | $19.38 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Endo USA, INC. | $17.86 | 2025 | Xiaflex |
| Helsinn Therapeutics (U.S.), INC. | $17.60 | 2023 | Valchlor |
| Lifenet Health | $17.26 | 2025 | Theragenesis Wound Matrix |
| Sun Pharmaceutical Industries INC. | $16.70 | 2023 | Blu-U, Odomzo |
| Biofrontera INC. | $16.59 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $15.60 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $14.99 | 2019 | |
| Sanara Medtech INC. | $14.85 | 2025 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.